RxDoctor Payments Data

Roger Oen, MD

Family Medicine · Coronado, CANPI 1710060165

Payments from drug & device makers

$4,843in general payments, 2019–2025

Across 152 payments — averaging $31.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$750
  • Boehringer Ingelheim$549
  • Lilly USA, LLC$549
  • Pfizer$422
  • AbbVie$409
  • Eisai Inc.$377
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$75015%
  • Food & beverage$4,08184%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,843 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$138,529
Medicare patients
350
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$128,199
JardianceEmpagliflozin55$82,085
XareltoRivaroxaban29$38,147
TrulicityDulaglutide23$37,205
EliquisApixaban20$25,998
Synjardy XrEmpagliflozin/Metformin Hcl13$23,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,703
Aimovig AutoinjectorErenumab-Aooe14$9,845
Breo ElliptaFluticasone/Vilanterol15$9,042
Rosuvastatin Calcium270$5,725
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,463
AdmelogInsulin Lispro12$3,461
Raloxifene Hcl39$2,852
Colchicine16$2,421
Atorvastatin Calcium223$2,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$128,199107 claims
Boehringer IngelheimJardiance, Synjardy Xr$549$106,00268 claims
Johnson & JohnsonXarelto$23$38,14729 claims
Lilly USA, LLCTrulicity$549$37,20523 claims
PfizerEliquis, Paxlovid$422$27,42731 claims
GSKTrelegy Ellipta, Breo Ellipta$207$21,74527 claims
AbbVieSynthroid$409$1,26323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Coronado

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →